Search Results - "Biasoni, D."

Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies by Procopio, G, Verzoni, E, Iacovelli, R, Biasoni, D, Testa, I, Porcu, L, De Braud, F

    Published in British journal of cancer (09-10-2012)
    “…Background: The most important prognostic factors for survival in patients with metastatic renal cell carcinoma (mRCC) were evaluated in the era of cytokine…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes by Necchi, A., Nicolai, N., Mariani, L., Raggi, D., Farè, E., Giannatempo, P., Catanzaro, M., Biasoni, D., Torelli, T., Stagni, S., Milani, A., Piva, L., Pizzocaro, G., Gianni, A.M., Salvioni, R.

    Published in Annals of oncology (01-11-2013)
    “…Since 1985, we introduced a modified combination of etoposide, ifosfamide, and cisplatin (PEI) as second-line therapy of adult male germ cell tumors with the…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test by Del Nero, A, Esposito, N, Currò, A, Biasoni, D, Montanari, E, Mangiarotti, B, Trinchieri, A, Zanetti, G, Serrago, M P, Pisani, E

    Published in European urology (01-02-1999)
    “…In the present study we compared the clinical value of two new specific tests for transitional cell carcinoma, urinary nuclear matrix protein (NMP22) levels…”
    Get more information
    Journal Article
  15. 15

    State of the Art and Controversies in the Treatment of Testis Germ-Cell Tumors (TGT) by Salvioni, R., Nicolai, N., Necchi, A., Torelli, T., Piva, L., Stagni, S., Catanzaro, M. A., Biasoni, D., Milani, A.

    Published in Urologia (01-10-2009)
    “…Many different, intersecting strategies are available for managing germ-cell cancers, particularly in early-stage disease. Which is ‘right’ remains a matter of…”
    Get full text
    Journal Article
  16. 16

    Retroperitoneal Surgery in the Treatment of Germ-Cell Tumors of the Testis: Retroperitoneal Lymph Node Dissection (RPLND) by Nicolai, N., Necchi, A., Piva, L, Stagni, S., Catanzaro, M.A., Biasoni, D., Milani, A., Torelli, T., Salvioni, R.

    Published in Urologia (01-04-2010)
    “…Germ-cell tumors of the testis (GCTT) are rare, but have a high social impact. In fact they represent no more than 1% of male tumors (about 700 new cases per…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19
  20. 20